Phase II trial of N-methylformamide in advanced head and neck cancer

Walter C. Vogel; Arlene A. Forastiere; Ronald B. Natale; Bonnie J. Takasugi; Gary Schnur

doi:10.1007/BF00203547

Phase II trial of N-methylformamide in advanced head and neck cancer

Walter C. Vogel, Arlene A. Forastiere, Ronald B. Natale, Bonnie J. Takasugi, Gary Schnur

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M² IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.

Original language	English (US)
Pages (from-to)	203-206
Number of pages	4
Journal	Investigational New Drugs
Volume	5
Issue number	2
DOIs	https://doi.org/10.1007/BF00203547
State	Published - Jun 1987
Externally published	Yes

Keywords

N-methylformamide
head and neck cancer
phase II trial

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00203547

Cite this

@article{26382ea8f96b49faadaf39d8ea19b6cc,

title = "Phase II trial of N-methylformamide in advanced head and neck cancer",

abstract = "Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.",

keywords = "N-methylformamide, head and neck cancer, phase II trial",

author = "Vogel, {Walter C.} and Forastiere, {Arlene A.} and Natale, {Ronald B.} and Takasugi, {Bonnie J.} and Gary Schnur",

year = "1987",

month = jun,

doi = "10.1007/BF00203547",

language = "English (US)",

volume = "5",

pages = "203--206",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase II trial of N-methylformamide in advanced head and neck cancer

AU - Vogel, Walter C.

AU - Forastiere, Arlene A.

AU - Natale, Ronald B.

AU - Takasugi, Bonnie J.

AU - Schnur, Gary

PY - 1987/6

Y1 - 1987/6

N2 - Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.

AB - Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.

KW - N-methylformamide

KW - head and neck cancer

KW - phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0023081030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023081030&partnerID=8YFLogxK

U2 - 10.1007/BF00203547

DO - 10.1007/BF00203547

M3 - Article

C2 - 3654153

AN - SCOPUS:0023081030

SN - 0167-6997

VL - 5

SP - 203

EP - 206

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase II trial of N-methylformamide in advanced head and neck cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this